Welcome to our dedicated page for Lensar SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LENSAR, Inc. (LNSR) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical device and global medical technology company. LENSAR files reports with the U.S. Securities and Exchange Commission that cover its financial performance, corporate governance, and significant corporate events.
Current reports on Form 8-K include items such as quarterly results announcements, scheduling of stockholder meetings, and the outcome of the special meeting at which stockholders approved the merger agreement with Alcon Research, LLC. For example, an 8-K dated July 2, 2025, details the vote to adopt the merger agreement under which Alcon intends to acquire LENSAR, with LENSAR surviving as a wholly owned subsidiary of Alcon Research, LLC upon completion of the transaction.
LENSAR also files a definitive proxy statement on Schedule 14A, which describes the annual meeting of stockholders, director elections, ratification of the independent registered public accounting firm, and aspects of corporate governance and executive and director compensation. The proxy materials outline board structure, committee responsibilities, risk oversight, and equity compensation plans.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review key sections with AI-powered assistance. Summaries can help explain complex topics such as merger proposals, non-GAAP financial measures referenced in earnings-related filings, and stockholder voting procedures. This page is a resource for understanding how LENSAR reports its operations, governance, and the progress of its planned acquisition by Alcon.
LENSAR, Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery, led by its ALLY Robotic Cataract Laser System. The ALLY System combines imaging, treatment planning and dual-modality laser capabilities in a compact unit designed for use in an operating room or in-office suite.
The company targets growing global cataract volumes and low current use of lasers, emphasizing improved visual outcomes, especially for patients with astigmatism choosing premium, largely out-of-pocket procedures. LENSAR highlights proprietary AI-driven imaging, Refractive Capsulorhexis, wireless data integration and a sizable patent portfolio as key competitive strengths, while noting risks including termination of a prior merger agreement, ongoing operating losses, regulatory demands, supply-chain pressures and the need for additional capital and continued market adoption of the ALLY System.
LENSAR, Inc. reported fourth quarter and full-year 2025 results showing a stronger recurring revenue base and growing adoption of its ALLY Robotic Cataract Laser System. Total revenue was $16.0 million in Q4 2025 and $58.4 million for 2025, up from $53.5 million in 2024, with recurring revenue reaching $46.3 million, or 79% of total for both Q4 and the year.
Q4 system revenue declined as the company placed 15 ALLY systems, but procedure-based revenue rose, with worldwide 2025 procedure volume up 22% to 206,014. The ALLY installed base grew 48% year over year to about 200 systems, and the combined laser installed base reached roughly 435 systems.
Despite higher acquisition-related costs tied to a previously contemplated merger with Alcon, net loss narrowed sharply in Q4 to $1.5 million versus $18.7 million a year earlier, mainly due to changes in warrant liability fair value. For 2025, net loss was $34.3 million. Cash, cash equivalents and investments totaled $18.0 million at December 31, 2025, and the company notes it will retain a $10.0 million merger deposit following termination of the Alcon transaction, while recognizing significant acquisition-related expenses.
LENSAR, Inc. Chief Financial Officer Thomas R. Staab II exercised stock options to acquire 5,500 shares of common stock at $2.65 per share. Following the transaction, he directly holds 175,959 shares of LENSAR common stock.
The exercised option is part of a grant that vested 25% on January 11, 2024, with the remainder vesting in thirty-six monthly installments, contingent on continued service. This filing reflects a routine compensation-related option exercise rather than an open-market purchase or sale.
LENSAR, Inc. announced that it has terminated its previously agreed merger with Alcon Research, LLC. The parties signed a Termination and Mutual Release Agreement on March 16, 2026, ending the deal and releasing each other from claims related to the merger.
Under the termination terms, LENSAR will retain the $10.0 million deposit that Alcon had provided. LENSAR states it understands the Federal Trade Commission intends to seek to enjoin the acquisition, and that required U.S. regulatory approvals were unlikely before the merger’s outside dates in April or July 2026.
The company says it will continue as an independent medical technology business focused on its ALLY Robotic Cataract Laser System and plans to report fourth quarter and full-year 2025 financial results and a strategic update on March 31, 2026.
LENSAR, Inc. filed an amended report to restate and clarify its disclosure about a new credit facility with Wells Fargo Bank, N.A. The company has entered into a Priority Credit Line Agreement that provides a revolving, non-purpose margin credit line secured by a first-priority lien on a designated brokerage account.
Based on the collateral value in this account, LENSAR may borrow up to $9.2 million. Borrowings accrue interest, at the company’s election, at either a fixed rate based on the Treasury Yield plus a margin over a chosen term, or a variable rate based on SOFR plus a margin. The agreement includes customary events of default tied to missed payments, collateral shortfalls, insolvency proceedings, and related security agreements.
LENSAR, Inc. has entered into a Priority Credit Line Agreement with Wells Fargo Bank, N.A. providing a revolving, non-purpose margin credit facility of up to $50 million, secured by a first-priority lien on a designated brokerage account at Wells Fargo.
Approximately $10 million in collateral has been deposited in this account to support borrowings. The company can choose interest based on either a fixed rate using the Treasury Yield plus a margin, or a variable rate using SOFR plus a margin. The agreement includes customary events of default such as missed payments, failure to post additional collateral, insolvency events, or insufficient collateral value.
LENSAR, Inc. provided an update on its pending acquisition by Alcon Research, LLC. The companies continue to work with U.S. Federal Trade Commission staff following a Request for Additional Information and Documentary Material, known as a Second Request, related to the proposed transaction.
Based on the current regulatory review process, LENSAR now expects the Alcon transaction to close in the first half of 2026, subject to satisfaction of closing conditions, including FTC approval. The company also highlights risks that the deal may be delayed, may not close, could be terminated with a potential termination fee, and that its stock price may decline significantly if the transaction is not completed.
LENSAR, Inc. Chief Operating Officer Alan B. Connaughton reported a tax-related share disposition tied to restricted stock units. On this Form 4, 2,392 shares of common stock were withheld by the company at a price of $11.32 per share to satisfy tax withholding obligations when RSUs vested. After this withholding transaction, Connaughton directly owned 357,069 shares of LENSAR common stock.
Lensar, Inc. Chief Financial Officer Thomas R. Staab II reported a tax-related share disposition tied to vesting of restricted stock units. On this event, 1,076 shares of common stock were withheld by the company at $11.32 per share to satisfy tax withholding obligations, rather than sold on the open market. Following this withholding, Staab’s direct ownership stands at 170,459 common shares.
LENSAR, Inc. Chief Executive Officer and director Nicholas T. Curtis reported an administrative Form 4 transaction coded as an "other acquisition or disposition" of common stock. A footnote explains that Mr. Curtis paid cash to cover tax withholding obligations related to previously vested restricted stock units, and the number of shares reported as beneficially owned did not change. Following this transaction, he continued to hold 992,096 shares of common stock directly.